Mitochondrion

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

Retrieved on: 
Thursday, August 11, 2022 - 9:05pm

The Company plans to submit a complete response to the CTI-1601 clinical hold in the third quarter of 2022.

Key Points: 
  • The Company plans to submit a complete response to the CTI-1601 clinical hold in the third quarter of 2022.
  • We look forward to receiving FDA feedback on the complete response and our proposed Phase 2 dose exploration study.
  • Research and development expenses for the second quarter of 2022 were $5.6 million compared to $9.1 million for the second quarter of 2021.
  • General and administrative expenses for the second quarter of 2022 were $3.0 million compared to $3.4 million for the second quarter of 2021.

Regain Your Energy Edge with Supercharged Mitochondria

Retrieved on: 
Thursday, August 11, 2022 - 5:00pm

CARLSBAD, Calif., Aug. 11, 2022 /PRNewswire/ -- Join DrTalks.com with the creator of "Reclaim Your Energy Edge," Laura Frontiero, FNP-BC, from Tuesday, August 23rd through Tuesday, August 30th for the Restore Your Mitochondrial Matrix Summit, a free virtual event exploring the impact of mitochondrial health on focus, energy, and productivity. Featured guests include Kashif Khan (CEO of The DNA Company), Cynthia Thurlow (Best-Selling Author), and Dr. Wendie Trubow (Functional Medicine Expert). Each expert will be interviewed directly by Laura Frontiero, FNP-BC.

Key Points: 
  • We all experience two kinds of energy: body energy and cellular energy.
  • Topics will center around mitochondrial health, including signs of mitochondrial dysfunction, ways to support healthy mitochondria, complementary treatments, and more.
  • Attendees will discover practical and effective ways to boost their energy, regain focus, and become the powerhouses of productivity they KNOW you can be - because they used to be!
  • Register for the Restore Your Mitochondrial Matrix Summit and reclaim your energy edge!

PFX Labs Release The Best Legal Phentermine Alternatives Chosen By Outlook India in 2022

Retrieved on: 
Thursday, August 11, 2022 - 2:00pm

Kington, Aug. 11, 2022 (GLOBE NEWSWIRE) -- PFX Labs impressive phentermine alternative ShredCBD won the vote by Outlook India as the best over the counter fat burning and weight loss solution with their range of successful studies and high-quality ingredients.

Key Points: 
  • Kington, Aug. 11, 2022 (GLOBE NEWSWIRE) -- PFX Labs impressive phentermine alternative ShredCBD won the vote by Outlook India as the best over the counter fat burning and weight loss solution with their range of successful studies and high-quality ingredients.
  • Winning a selection of prestigious awards, including the International Press Institute award for Excellence in Journalism, Outlook India has now drawn their attention to presenting to their readers the best and most effective phentermine alternatives for weight loss and management.
  • Their specialised phentermine alternative formula is safe and made with science-backed ingredients that have shown to help support peak metabolic health.
  • To read more about Outlook Indias article on PFX Labs ShredCBD and Wolfson Brands Ltd PhenQ, please visit their website at https://www.outlookindia.com/outlook-spotlight/alternatives-to-phentermi... .

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022 - 1:00pm

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.

Key Points: 
  • IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.
  • The second quarter was a very productive period for the company, highlighted by advancements in both of our mitochondrial disease programs, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • The Company had approximately $127 million in cash, cash equivalents and short-term investments as of June30, 2022.
  • Research and development expenses for the three months ended June30, 2022 were $8.1 million, compared to $6.3 million for the three months ended June30, 2021.

The Root Brands Releases its 7th product Mitochondria Defense Shield with NAD

Retrieved on: 
Saturday, August 6, 2022 - 1:24am

Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.

Key Points: 
  • Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.
  • Mitochondria are tiny double membrane-bound organelles found in almost every cell of all organisms except bacteria, they are known as "the powerhouse of the cell".
  • It enters the mitochondria in its oxidized form and protects mitochondria from oxidative injury.
  • Vitamin D is vital for regulating the absorption of calcium and phosphorus and facilitating normal immune system function.

Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Retrieved on: 
Wednesday, August 3, 2022 - 1:00pm

In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.

Key Points: 
  • In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.
  • The Phase 1b portion of the trial enrolled 20 patients and concluded that the combination of gemcitabine and cisplatin with devimistat is well tolerated.
  • The randomized Phase 2 portion of the trial is open and accruing patients across 10 cancer centers in the U.S., targeting an enrollment of 78 patients.
  • Advanced biliary tract cancer is a rare and aggressive form of cancer with a 5-year survival rate of less than 5%.

Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

Retrieved on: 
Tuesday, August 2, 2022 - 12:30pm

IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the companys Board of Directors.

Key Points: 
  • IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the companys Board of Directors.
  • Roshawn is an accomplished leader within the biopharma industry, said Mike Grey, Executive Chairman of Reneo Pharmaceuticals.
  • I am thrilled to join the Reneo Board, said Ms. Blunt.
  • Reneo is an extraordinary company with a novel drug that has the potential to treat a number of mitochondrial diseases.

CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022

Retrieved on: 
Monday, August 1, 2022 - 2:00pm

ET (2:00 p.m. PT) on the same day to provide an update on the companys business.

Key Points: 
  • ET (2:00 p.m. PT) on the same day to provide an update on the companys business.
  • An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on August 15, 2022, through 11:59 p.m. Eastern Time on September 5, 2022.
  • To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13730421.
  • For additional company information, please visit www.cohbar.com and engage with us on LinkedIn.

Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates

Retrieved on: 
Tuesday, July 26, 2022 - 12:30pm

We are very encouraged by the results of the LC-FAOD Phase1b study, said Dr. Alejandro Dorenbaum, Chief Medical Officer of Reneo Pharmaceuticals, Inc. Safety and tolerability of REN001 in this study was consistent with prior REN001 studies.

Key Points: 
  • We are very encouraged by the results of the LC-FAOD Phase1b study, said Dr. Alejandro Dorenbaum, Chief Medical Officer of Reneo Pharmaceuticals, Inc. Safety and tolerability of REN001 in this study was consistent with prior REN001 studies.
  • The Company intends to present additional data from the LC-FAOD studies at a medical conference in 2022.
  • Over two-thirds of the patients have been enrolled into the 24-week study, with enrollment on track to be completed by year-end 2022.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®

Retrieved on: 
Wednesday, July 20, 2022 - 6:30am

Year 5 values were the LogMAR readings nearest to 1,825 days post treatment recorded between 1,825 +/- 28 days post-treatment.

Key Points: 
  • Year 5 values were the LogMAR readings nearest to 1,825 days post treatment recorded between 1,825 +/- 28 days post-treatment.
  • Responder analyses at Year 5 indicate that improved BCVA was a benefit for a substantial proportion of the study participants.
  • Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset.
  • The primary objective is to assess the long-term safety of intravitreal LUMEVOQ administration up to 5 years post-treatment.